Latest Breaking News On - Investor relations calendar - Page 1 : comparemela.com

Napco Security Technologies, Inc (NASDAQ:NSSC) Q2 2024 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the NAPCO Security Technologies Fiscal Second Quarter of 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Dominican republicFran okoniewskiLas vegasKevin buchelFrancis okoniewskiJaeson schmidtRichard solowayNapco security technologies incNapco security technologiesCall transcript februarySecurity technologiesTechnologies fiscal second quarterVice presidentInvestor relationsChief executive officerExecutive vice president

Faron to Hold Conference Call to Discuss New Positive

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage.

United statesJenniferc smith parkerSandy jamiesonJuha karttunenJo turnerChristopher goldenFaron pharmaceuticalsPeel huntHead of communicationsFaron pharmaceuticals ltdCairn financial advisersFirst northInvestor relations calendarCertified adviserNasdaq firstLondon stock exchange farn

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study. Conference Call and Webcast Wednesday, July 19, 2023, at 8:30 am ET. The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201)

United statesChristopher goldenJuha karttunenSandy jamiesonJenniferc smith parkerJo turnerFaron pharmaceuticals ltdFaron pharmaceuticalsHead of communicationsPeel huntCairn financial advisersFirst northInvestor relations calendarCertified adviserNasdaq firstBiopharmaceutical company

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Eteläuomen läiUnited statesJenniferc smith parkerChristopher goldenSandy jamiesonJuha karttunenJo turnerMika kontroPeel huntHead of communicationsFaron pharmaceuticals ltdHelsinki university hospital comprehensive cancer centerEuropean hematology associationFaron pharmaceuticalsCairn financial advisersBiologics license application

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJessica yinglingSandra rojas caroNeubase therapeuticsneubaseDan ferrymanaging directorlifesciDietricha stephanNeubase therapeutics incExchange commissionPh dlittle dog communications incLeaders world congressDrug administrationWebcast detailsneubase therapeutics incMyotonic dystrophy typeInvestigational new drugBase therapeutics